Axiom Investors LLC DE Raises Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Axiom Investors LLC DE lifted its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 208.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,752,430 shares of the medical equipment provider's stock after acquiring an additional 2,535,007 shares during the period. Boston Scientific makes up about 2.5% of Axiom Investors LLC DE's holdings, making the stock its 11th largest holding. Axiom Investors LLC DE owned 0.25% of Boston Scientific worth $335,167,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the stock. D.A. Davidson & CO. grew its holdings in Boston Scientific by 3.2% during the 3rd quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider's stock valued at $917,000 after buying an additional 342 shares in the last quarter. Townsquare Capital LLC grew its stake in Boston Scientific by 191.9% during the third quarter. Townsquare Capital LLC now owns 26,896 shares of the medical equipment provider's stock valued at $2,254,000 after acquiring an additional 17,683 shares in the last quarter. Glenmede Trust Co. NA increased its holdings in Boston Scientific by 19.0% during the 3rd quarter. Glenmede Trust Co. NA now owns 20,463 shares of the medical equipment provider's stock worth $1,715,000 after acquiring an additional 3,261 shares during the period. CreativeOne Wealth LLC lifted its stake in Boston Scientific by 62.0% in the 3rd quarter. CreativeOne Wealth LLC now owns 4,478 shares of the medical equipment provider's stock worth $375,000 after purchasing an additional 1,714 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its holdings in Boston Scientific by 0.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 33,367 shares of the medical equipment provider's stock valued at $2,796,000 after purchasing an additional 263 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on BSX. Piper Sandler upped their price target on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. JPMorgan Chase & Co. upped their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. Royal Bank of Canada lifted their price target on Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Truist Financial upped their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Finally, Morgan Stanley lifted their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the company an "overweight" rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Boston Scientific currently has an average rating of "Moderate Buy" and an average target price of $108.91.

Boston Scientific Trading Down 8.9 %

BSX stock traded down $8.73 during trading on Friday, hitting $89.78. 22,572,180 shares of the company traded hands, compared to its average volume of 6,184,788. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The company has a 50-day moving average of $101.90 and a 200-day moving average of $93.55. The firm has a market capitalization of $132.78 billion, a PE ratio of 71.82, a P/E/G ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 1 year low of $66.80 and a 1 year high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, EVP Jeffrey B. Mirviss sold 4,675 shares of Boston Scientific stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $104.25, for a total value of $487,368.75. Following the sale, the executive vice president now directly owns 28,454 shares in the company, valued at approximately $2,966,329.50. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Bradley Sorenson sold 6,528 shares of the company's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $104.97, for a total value of $685,244.16. Following the transaction, the executive vice president now owns 26,449 shares of the company's stock, valued at approximately $2,776,351.53. This represents a 19.80 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 133,183 shares of company stock worth $13,948,476. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.